Depomed Inc (DEPO) is Reiterated by Mizuho to Buy, Raises Price Target to $ 27

Depomed Inc (DEPO) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 27 from a previous price target of $23 . Mizuho advised their investors in a research report released on Sep 19, 2016.

Many Wall Street Analysts have commented on Depomed Inc. Company shares were Reiterated by Mizuho on Sep 19, 2016 to “Buy”, Firm has raised the Price Target to $ 27 from a previous price target of $23 .Depomed Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 27, 2016. UBS Downgraded Depomed Inc on Jul 7, 2016 to ” Neutral”, Price Target of the shares are set at $20.

On the company’s financial health, Depomed Inc reported $0.27 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.26. The company had revenue of $116.70 million for the quarter, compared to analysts expectations of $118.48 million. The company’s revenue was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.

Depomed Inc opened for trading at $23.99 and hit $24.45 on the upside on Friday, eventually ending the session at $24.34, with a gain of 14.60% or 3.1 points. The heightened volatility saw the trading volume jump to 8,542,433 shares. Company has a market cap of $1,494 M.

In a different news, on Aug 11, 2016, August J Moretti (Chief Financial Officer & SVP) sold 5,000 shares at $21.40 per share price. According to the SEC, on Aug 11, 2016, Thadd M Vargas (Senior VP, BD) sold 26,290 shares at $20.92 per share price.

Depomed Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include Gralise (gabapentin) CAMBIA (diclofenac potassium for oral solution) Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor a liquid filled capsule is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Company’s product DM-1992 has completed a Phase II trial for Parkinson’s disease.

Depomed Inc

Leave a Reply

Depomed Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Depomed Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.